Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06452212

Non-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer Patients

Metastatic Hormone-Sensitive Prostate Cancer Clinical Trial

Official title:
A Non-Interventional, Modified Delphi Study to Establish Consensus Recommendations on the Optimal Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Patients in South Korea

Clinical Trial Summary

The purpose of this study is to establish an expert consensus recommendations on managing patients with mHSPC in South Korea, and to provide clinicians with a comprehensive guide to support their clinical decision making. There are no secondary objectives for this study.

Clinical Trial Description

Data collection for this study will be conducted through 2 rounds of web-based surveys of health care professionals (HCPs). A meeting with the panelists will be held as a 3rd round if a consensus for pre determined key questions is not achieved after the 2 rounds of the survey. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06452212
Study type Observational
Source Astellas Pharma Inc
Contact Astellas Pharma Korea, Inc.
Phone +82 -2-3448-0504
Email Astellas.registration@astellas.com
Status Not yet recruiting
Phase
Start date July 31, 2024
Completion date September 30, 2024
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06334120 - An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea
Completed NCT05381311 - Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study
Active, not recruiting NCT00309985 - Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer Phase 3
Completed NCT03532217 - Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer Phase 1
Active, not recruiting NCT05059236 - A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study. Phase 2
Completed NCT02799602 - Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer Phase 3
Not yet recruiting NCT06134271 - Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer Phase 2
Active, not recruiting NCT04934722 - Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension Phase 3
Recruiting NCT05901649 - A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide
Withdrawn NCT03343977 - Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Phase 1/Phase 2
Active, not recruiting NCT04191096 - Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) Phase 3
Active, not recruiting NCT03879122 - A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer Phase 2/Phase 3